Skip to main content
MedPathMedPath Home
Clinical Trials/NCT02164500
NCT02164500
Completed
Phase 2

A Phase II, Open-label, Prospective, Non-randomized, Multicenter Clinical Trial With the JAK-inhibitor Ruxolitinib in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

University of Cologne1 site in 1 country12 target enrollmentOctober 2015
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsRecurrent Classical Hodgkin Lymphoma
InterventionsRuxolitinib
DrugsRuxolitinib

Overview

Phase
Phase 2
Intervention
Ruxolitinib
Conditions
Recurrent Classical Hodgkin Lymphoma
Sponsor
University of Cologne
Enrollment
12
Locations
1
Primary Endpoint
overall response rate
Status
Completed
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaArms & InterventionsOutcomesSitesSimilar Trials

Overview

Brief Summary

The Purpose of this trial is:

  • to determine the overall response rate (ORR, complete response [CR] + partial response [PR]) in patients with relapsed or refractory HL
  • to determine the safety profile of ruxolitinib in patients with relapsed or refractory HL
Registry
clinicaltrials.gov
Start Date
October 2015
End Date
May 17, 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dr. Bastian von Tresckow

Dr.

University of Cologne

Eligibility Criteria

Inclusion Criteria

  • •relapsed or refractory HL
  • •ECOG \<= 2,
  • •no major organ dysfunction
  • •written informed consent

Exclusion Criteria

  • •history of another primary malignancy ≤ 2 years
  • •female patients who are pregnant or breast feeding
  • •patients with a known history of HIV seropositivity
  • •chronic active hepatitis

Arms & Interventions

Ruxolitinib

Intervention: Ruxolitinib

Outcomes

Primary Outcomes

overall response rate

Time Frame: 8 weeks

Study Sites (1)

Loading locations...

Similar Trials

Terminated
Phase 2
An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular LymphomaLymphoma, Mantle-CellLymphoma, Large B-Cell, DiffuseLymphoma, Follicular
NCT02413489Janssen Research & Development, LLC36
Terminated
Phase 2
A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)Thyroid Carcinoma, Anaplastic
NCT02657369Eisai Inc.34
Terminated
Phase 2
Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic LeukemiaChronic Lymphocytic Leukemia
NCT00792831Italfarmaco3
Completed
Phase 2
Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and NeckSquamous Cell Carcinoma of Head and Neck
NCT02061631Sanofi35
Terminated
Phase 2
Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.High Risk MDS
NCT02159040Novartis Pharmaceuticals1